After discussions with the FDA, Moderna has withdrawn its application for a combination shot, which had demonstrated efficacy ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

From a higher bar for regulatory clearance to pricing limitations, drug development is more expensive than ever. This has led ...

Most of the 15 million children with a rare disease have no FDA-approved treatments available to them. And when it comes to ...

After a tense exchange, Senator Patty Murray (D-WA) told Kennedy that by implementing sweeping cuts to the HHS, he is ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

The Most Favored Nation order is unlikely to deliver broad, sustained savings without triggering legal challenges, ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director ...